Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Hepatitis A - Management
How should I manage a person with confirmed or probable hepatitis A infection?

  • Notify the local Health Protection Unit promptly — hepatitis A is a notifiable disease.
  • There is no specific anti-viral treatment for hepatitis A.
  • Review the person's medication.
    • Stop non-essential medication during the acute illness.
    • Avoid using sedatives in those with severe disease (because of the risk of sedation and coma).
  • If pain relief is required, suitable options include:
    • Ibuprofen.
    • Paracetamol — normal dosages can be used, unless there is evidence of moderate or severe liver impairment. If serum bilirubin is greater than 300 micromoles/L or prothrombin time is greater than 3 seconds, reduce to a maximum of 1 g twice or three times a day.
    • A weak opioid (such as codeine) may be used if liver impairment is mild. Avoid codeine in severe liver impairment (enhanced sedative effects and reduced clearance).
  • If treatment of nausea is required, and liver impairment is mild, offer metoclopramide or cyclizine at normal dosage. Seek specialist advice on the dosage and choice of anti–emetic if the person has more severe liver impairment.
  • Itch can be difficult to treat.
    • Advise simple measures (such as maintaining a cool, well-ventilated environment, wearing loose clothing, and avoiding hot baths or showers).
    • Consider offering chlorphenamine at normal dosage at night (although avoid this in severe liver impairment). This can be increased to use every 4–6 hours if itch is severe. Ursodeoxycholic acid, colestyramine, and corticosteroids are other treatment options — seek specialist advice before prescribing.
  • Monitor liver function and prothrombin time. As a general guide:
    • Monitor liver function and prothrombin time 3–5 days after diagnosis, then weekly until improvement is seen. Monitoring can then be reduced to fortnightly and then monthly until liver function normalizes (usually 4–12 weeks).
      • If the person is jaundiced or symptomatic, monitor twice a week.
      • Monitor every 1–2 days in people with more severe liver disease (for example where aspartate aminotransferase [AST] or alanine aminotransferase [ALT] is greater than 2000 IU/L, bilirubin is greater than 300 micromoles/L, or prothrombin time is greater than 3 seconds).
  • Screen for other sexually transmitted infections, if sexually-acquired hepatitis is suspected.
  • Advise the person to:
    • Rest when necessary.
    • Avoid drinking alcohol during the acute illness.
    • Return if there is any deterioration in their condition.

© NHS Institute for Innovation and Improvement